Overview
- The collaboration integrates Mabqi’s LiteMab Antibody Discovery Studio—using universal and pH‑sensitive libraries—with Abzena’s developability, cell line, process development, and GMP services.
- The companies position the combined workflow to bridge discovery through lead selection into preclinical development with fewer handoffs.
- Executives said data-driven screening and early developability assessments will streamline programs and shorten time to the clinic.
- The integrated offering spans monoclonal antibodies, mAb fragments, bi- and multi-specifics, and bioconjugates, including antibody-drug conjugates.
- The announcement did not disclose financial terms, customer programs, or specific timelines.